Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.

@article{Heymach2008RandomizedPI,
  title={Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.},
  author={John V. Heymach and Luis Paz-Ares and Filippo Guglielmo de Braud and Martin Sebastian and David J. Stewart and Wilfried Ernst Erich Eberhardt and Anantbhushan A Ranade and Graham Cohen and Jos{\'e} Manuel Trigo and Alan B. Sandler and Philip D. Bonomi and Roy S. Herbst and Annetta D Krebs and James R. Vasselli and Bruce Evan Johnson},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 33},
  pages={5407-15}
}
PURPOSE Vandetanib is a once-daily, oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. The antitumor activity of vandetanib monotherapy or vandetanib with paclitaxel and carboplatin (VPC) was compared with paclitaxel and carboplatin (PC) in previously untreated patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS All NSCLC histologies and previously treated CNS metastases were permitted in this partially blinded… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
102 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 102 extracted citations

Similar Papers

Loading similar papers…